The relationship between the use of immunosuppressants in solid-organ transplant patients and oral tissue abnormalities has been recognized. The objective of this study was to determine the state of oral tissue integrity in renal, heart, and liver transplant patients who are on continuous medical and dental control. Forty patients of both sexes were clinically evaluated at the Clinical Hospital of the University of Chile to identify pathologies of oral mucosa, gingival enlargement (GE), decayed, missing, filled teeth (DMFT) index, and salivary flow. The average age of the transplant subjects was 49.4 years, and the age range was 19 to 69 years. Most subjects maintained a good level of oral hygiene, and the rate mean of DMFT was 14.7. The degree of involvement of the oral mucosa and GE was low (10%). Unlike other studies, the frequency of oral mucosal diseases and GE was low despite the fact that these patients were immunosuppressed. Care and continuous monitoring seem to be of vital importance in maintaining the oral health of transplant patients. 1. Introduction Organ transplantation is a widely used treatment for the functional failure of an organ. The life expectancies of patients who have received heart, lung, kidney, liver, or bone marrow transplants have improved substantially in recent years [1], partly due to improvements in surgical techniques and the immunosuppressive drug therapies used to prevent transplant rejection [1]. From 1992 to 2009 in Chile, there have been a total of 4570 solid-organ transplants, including 3494 kidney transplants, 768 liver transplants, and 198 heart transplants [2]. Immunosuppressive therapy has a number of short- and long-term effects including infection, increased cardiovascular risk, and neoplasm that may threaten the patient’s life [3, 4]. This treatment depresses the cellular immune response [5]. Cyclosporin A, the most widely used immunosuppressive drug, acts selectively on T-cell-mediated immune responses [1]. Clinically, this effect means a high risk of oral infections and associated complications. In patients who are treated with immunosuppressants, oral pathogens can cause local destruction and opportunistic infections due to the inability of the immune system to suppress and destroy pathogens. Lesions in the oral cavity could develop as a result of these side effects or drug interactions [5]. At the periodontal level, gingival enlargement (GE) associated with immunosuppressive therapy with cyclosporin A usually appears within the first 12 months of use [6], and the risk is increased with the concomitant
References
[1]
R. A. Seymour, J. M. Thomason, and A. Nolan, “Oral lesions in organ transplant patients,” Journal of Oral Pathology and Medicine, vol. 26, no. 7, pp. 297–304, 1997.
[2]
“Corporación del Trasplante,” http://www.trasplante.cl/index.php.
[3]
A. Andrés, “Cancer incidence after immunosuppressive treatment following kidney transplantation,” Critical Reviews in Oncology/Hematology, vol. 56, no. 1, pp. 71–78, 2005.
[4]
M. L. Díaz Ortiz, J. M. Micó-Llorens, J. G. Albiol, C. B. Comellas, L. B. Aytés, and C. G. Escoda, “Dental health in liver transplant patients,” Medicina Oral, Patología Oral y Cirugía Bucal, vol. 10, no. 1, pp. 66–72, 2005.
[5]
E. Parisi and M. Glick, “Immune suppression and considerations for dental care,” Dental Clinics of North America, vol. 47, no. 4, pp. 709–731, 2003.
[6]
R. A. Seymour and D. J. Jacobs, “Cyclosporin and the gingival tissues,” Journal of Clinical Periodontology, vol. 19, no. 1, pp. 1–11, 1992.
[7]
K. V. Greenberg, G. C. Armitage, and C. H. Shiboski, “Gingival enlargement among renal transplant recipients in the era of new-generation immunosuppressants,” Journal of Periodontology, vol. 79, no. 3, pp. 453–460, 2008.
[8]
L. O. M. Cota, D. R. Aquino, G. C. N. Franco, J. R. Cortelli, S. C. Cortelli, and F. O. Costa, “Gingival overgrowth in subjects under immunosuppressive regimens based on cyclosporine, tacrolimus, or sirolimus,” Journal of Clinical Periodontology, vol. 37, no. 10, pp. 894–902, 2010.
[9]
R. B. Lima, V. Benini, and Y. A. S. Sens, “Gingival overgrowth in renal transplant recipients: a study concerning prevalence, severity, periodontal, and predisposing factors,” Transplantation Proceedings, vol. 40, no. 5, pp. 1425–1428, 2008.
[10]
M. L. Somacarrera, G. Hernández, J. Acero, and B. S. Moskow, “Factors related to the incidence and severity of cyclosporin-induced gingival overgrowth in transplant patients. A longitudinal study,” Journal of Periodontology, vol. 65, no. 7, pp. 671–675, 1994.
[11]
M. Sahebjamee, M. S. Shahabi, M. R. Nikoobakht, J. M. Beitollahi, and A. Mansourian, “Oral lesions in kidney transplant patients,” Iranian Journal of Kidney Diseases, vol. 4, no. 3, pp. 232–236, 2010.
[12]
A. T. Güle？ and M. Haberal, “Lip and oral mucosal lesions in 100 renal transplant recipients,” Journal of the American Academy of Dermatology, vol. 62, no. 1, pp. 96–101, 2010.
[13]
M. A. Al-Mohaya, A. M. Darwazeh, S. Bin-Salih, and W. Al-Khudair, “Oral lesions in Saudi renal transplant patients,” Saudi Journal of Kidney Diseases and Transplantation, vol. 20, no. 1, pp. 20–29, 2009.
[14]
E. D. L. R. de la Rosa-García, A. Mondragón-Padilla, M. E. Irigoyen-Camacho, and M. A. B. Ramírez, “Oral lesions in a group of kidney transplant patients,” Medicina Oral, Patología Oral y Cirugía Bucal, vol. 10, no. 3, pp. 196–204, 2005.
[15]
L. C. Spolidorio, D. M. P. Spolidorio, E. M. S. Massucato, K. H. Neppelenbroek, N. H. Campanha, and M. H. Sanches, “Oral health in renal transplant recipients administered cyclosporin A or tacrolimus,” Oral Diseases, vol. 12, no. 3, pp. 309–314, 2006.
[16]
A. Dongari-Bagtzoglou, P. Dwivedi, E. Ioannidou, M. Shaqman, D. Hull, and J. Burleson, “Oral Candida infection and colonization in solid organ transplant recipients,” Oral Microbiology and Immunology, vol. 24, no. 3, pp. 249–254, 2009.
[17]
R. M. López-Pintor, G. Hernández, L. de Arriba, and A. de Andrés, “Comparison of oral lesion prevalence in renal transplant patients under immunosuppressive therapy and healthy controls,” Oral Diseases, vol. 16, no. 1, pp. 89–95, 2010.
[18]
J. Naranjo, J. Poniachik, D. Cisco et al., “Oral ulcers produced by mycophenolate mofetil in two liver transplant patients,” Transplantation Proceedings, vol. 39, no. 3, pp. 612–614, 2007.
[19]
S. W. Redding and S. M. Gordon, “Oral herpes simplex virus infection with cardiac transplantation,” Special Care in Dentistry, vol. 10, no. 6, pp. 196–199, 1990.
[20]
A. Macario-Barrel, S. Tanasescu, P. Courville et al., “Mouth ulcers in patients receiving tacrolimus,” Annales de Dermatologie et de Venereologie, vol. 128, no. 12, pp. 1327–1329, 2001.
[21]
A. Tabaee, B. Saltman, J. Shutter, H. Hibshoosh, and A. Markowitz, “Recurrent oral herpes simplex virus infection presenting as a tongue mass,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 97, no. 3, pp. 376–380, 2004.
[22]
J. C. Greene, “The oral hygiene index—development and uses,” Journal of Periodontology, vol. 38, no. 6, pp. 625–637, 1967.
[23]
P. López-Jornet, F. Camacho-Alonso, and A. Bermejo-Fenoll, “A simple test for salivary gland hypofunction using oral Schirmer's test,” Journal of Oral Pathology and Medicine, vol. 35, no. 4, pp. 244–248, 2006.
[24]
C. O. Enwonwu, R. S. Phillips, and W. A. Falkler Jr., “Nutrition and oral infectious diseases: state of the science,” Compendium of Continuing Education in Dentistry, vol. 23, no. 5, pp. 431–434, 2002.
[25]
K. E. Goldman, “Dental management of patients with bone marrow and solid organ transplantation,” Dental Clinics of North America, vol. 50, no. 4, pp. 659–676, 2006.
[26]
C. A. Okoro, T. W. Strine, P. I. Eke, S. S. Dhingra, and L. S. Balluz, “The association between depression and anxiety and use of oral health services and tooth loss,” Community Dentistry and Oral Epidemiology. In press.
[27]
H. S. Brand, C. P. Bots, and J. E. Raber-Durlacher, “Xerostomia and chronic oral complications among patients treated with haematopoietic stem cell transplantation,” British Dental Journal, vol. 207, no. 9, p. 429, 2009.
[28]
A. Almst？hl and M. Wikstr？m, “Electrolytes in stimulated whole saliva in individuals with hyposalivation of different origins,” Archives of Oral Biology, vol. 48, no. 5, pp. 337–344, 2003.
[29]
W. C. Gonsalves, A. S. Wrightson, and R. G. Henry, “Common oral conditions in older persons,” American Family Physician, vol. 78, no. 7, pp. 845–852, 2008.
[30]
L. Antoniewicz, D. Relijc, C. Poitschek, E. Presterl, and A. Geusau, “Mucosal Candida infection and colonisation as well as associated risk factors in solid organ transplant recipients,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 28, no. 8, pp. 945–957, 2009.
[31]
A. Ghafari, R. Poorabbas, J. A. Takieh, N. Sepehrvand, C. Kargar, and S. Hatami, “Gingival enlargement and its risk factors in kidney transplant patients receiving cyclosporine A,” Iranian Journal of Kidney Diseases, vol. 4, no. 1, pp. 66–70, 2010.
[32]
A. Darwazeh and A. A. Almelaih, “Tongue lesions in a Jordanian population. Prevalence, symptoms, subject's knowledge and treatment provided,” Medicina Oral, Patología Oral y Cirugía Bucal, vol. 16, no. 6, pp. 745–749, 2011.
[33]
C. L. Koay, J. A. Lim, and C. H. Siar, “The prevalence of tongue lesions in Malaysian dental outpatients from the Klang Valley area,” Oral Diseases, vol. 17, no. 2, pp. 210–216, 2011.
[34]
A. Jainkittivong, V. Aneksuk, and R. P. Langlais, “Oral mucosal lesions in denture wearers,” Gerodontology, vol. 27, no. 1, pp. 26–32, 2010.
[35]
J. Gamonal, C. Mendoza, I. Espinoza et al., “Clinical attachment loss in Chilean adult population: first Chilean national dental examination survey,” Journal of Periodontology, vol. 81, no. 10, pp. 1403–1410, 2010.
